Summary
Medtronic plc (MDT) reported strong financial results for the period ending October 25, 2024, showcasing a notable increase in both revenue and net income compared to the prior year. Net sales grew to $8.403 billion for the quarter and $16.318 billion for the six-month period, representing a 5% and 4% increase, respectively. Diluted earnings per share (EPS) rose significantly to $0.99 for the quarter and $1.79 for the six months, up from $0.68 and $1.28 in the prior year, respectively. This performance was driven by robust growth across key segments, including Cardiovascular, Neuroscience, and Diabetes, with specific product lines like the MiniMed 780G insulin pump system and structural heart devices showing particularly strong adoption. The company also demonstrated improved operational efficiency, with net cash provided by operating activities increasing to $1.944 billion for the six months ended October 25, 2024, contributing to a free cash flow of $1.020 billion. Medtronic successfully managed its debt, issuing €3.0 billion in Euro-denominated senior notes to enhance its financial flexibility, while continuing its share repurchase program. Despite some ongoing legal and regulatory matters, the company maintains a strong liquidity position and believes it is well-positioned to meet its operational needs and pursue strategic growth initiatives.
Financial Highlights
54 data points| Revenue | $8.40B |
| Cost of Revenue | $2.95B |
| Gross Profit | $5.46B |
| SG&A Expenses | $2.76B |
| Operating Income | $1.59B |
| Net Income | $1.27B |
| EPS (Basic) | $0.99 |
| EPS (Diluted) | $0.99 |
| Shares Outstanding (Basic) | 1.28B |
| Shares Outstanding (Diluted) | 1.29B |
Key Highlights
- 1Total net sales increased by 5% to $8.4 billion for the quarter and 4% to $16.3 billion for the six months, demonstrating consistent top-line growth.
- 2Diluted EPS saw a significant improvement, rising to $0.99 for the quarter and $1.79 for the six months, indicating enhanced profitability.
- 3The Cardiovascular segment reported a 6% sales increase for both the quarter and six months, driven by TAVR, Cardiac Rhythm Management, and Cardiac Surgery.
- 4The Diabetes segment experienced strong growth with a 12% increase in net sales for both periods, largely due to the MiniMed 780G system adoption.
- 5Net cash provided by operating activities increased to $1.94 billion for the six months, contributing to a robust free cash flow of $1.02 billion.
- 6Medtronic successfully issued €3.0 billion in Euro-denominated senior notes, strengthening its liquidity and financial flexibility.
- 7The company maintained strong credit ratings from S&P and Moody's, reflecting its sound financial health.